Gates Foundation Strategic Investment Fund Logo
Share this page:


Arsanis Logo

Arsanis is focused on discovery and development of novel monoclonal antibodies (“mAbs”) to prevent and treat infectious disease. The foundation is working with Arsanis to develop a prophylactic mAb candidate targeting Stap aureus, a leading cause of neonatal sepsis which leads to approximately 345,000 annual deaths globally. The foundation is also working with Arsanis to identify a prophylactic mAb candidate targeting RSV, which leads to nearly 120,000 annual children deaths globally.

Investment Date: April 2017

Press Release
News Story